Expression, Prognostic Value, and Immune Infiltration of MTHFD Family
in Bladder Cancer
-
Published:2024-02
Issue:2
Volume:24
Page:178-191
-
ISSN:1568-0096
-
Container-title:Current Cancer Drug Targets
-
language:en
-
Short-container-title:CCDT
Author:
Zheng Bai Shu1,
Wang Shun De2,
Zhang Jun Yong1ORCID,
Ge Cheng Guo1
Affiliation:
1. Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China
2. Department of Urology, The ChenJiaqiao Hospital of ShaPingba District of Chongqing City, Chongqing, 401331,
China
Abstract
Background:
The Methylenetetrahydrofolate Dehydrogenase (MTHFD) family plays an
important role in the development and prognosis of a variety of tumors; however, the role of the
MTHFD family in bladder cancer is unclear.
Methods:
R software, cBioPortal, GeneMANIA, and online sites such as String-LinkedOmics were
used for bioinformatics analysis.
Results:
MTHFD1/1L/2 was significantly upregulated in bladder cancer tissues compared with normal
tissues, high expression of the MTHFD family was strongly associated with poorer clinical
grading and staging, and bladder cancer patients with upregulated expression of MTHFD1L/2 had
a significantly worse prognosis. Gene function and PPI network analysis revealed that the MTHFD
family and related genes play synergistic roles in the development of bladder cancer. 800 co-expressed
genes related to the MTHFD family were used for functional enrichment analysis, and the
results showed that many genes were associated with various oncogenic pathways such as cell cycle
and DNA replication. More importantly, the MTHFD family was closely associated with multiple
infiltrating immune lymphocytes, including Treg cells, and immune molecules such as TNFSF9,
CD274, and PDCD1.
Conclusion:
Our study shows that MTHFD family genes may be potential prognostic markers and
therapeutic targets for patients with bladder cancer.
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Drug Discovery,Pharmacology,Oncology